

EUROPEAN SOCIETY OF PATHOLOGY NEWSLETTER

Autumn 2021



TAKE A
LOOK
INSIDE

Editor:
Prof. Marina Kos
Associate Editor:
Prof. Karoline Lackner
Lay-out and proofreading:
Malgorzata Short

Table of Contents

MESSAGE FROM THE PRESIDENT OF THE ESP	2
(By Prof. Aleš Ryška).....	2
MESSAGE FROM THE EDITOR	4
(By Prof. Marina Kos)	4
INTRODUCING THE NEW SECRETARY.	6
(By Prof. Janina Kulka)	6
MESSAGE FROM THE FORMER SECRETARY	7
(By Prof. Aurelio Ariza)	7
ESP INTERVIEWS SERIES	8
PRESENTING THE POLISH SOCIETY OF PATHOLOGY	12
(By Prof. Andrzej Marszalek).....	12
MESSAGE FROM THE ESP TRAINEE SUBCOMMITTEE	13
(By Dr Alexandra Vilaia and Dr Lee Seung Hyun)	13
NEWS FROM THE EUROPEAN CANCER ORGANISATION (ECO).....	15
(By Paul Gasc, Special Projects Lead, European Cancer Organisation).....	15
OBITUARY OF PROFESSOR MICHAEL NEWTON MARSH	16
(By Prof. Arzu Ensari).....	16
RECENTLY PUBLISHED BOOKS	17
(By Prof. Karoline Lackner)	17
UPCOMING WEBINARS AND CONFERENCES.....	18
(By Prof. Karoline Lackner)	18

Message from the President of the ESP

(By Prof. Aleš Ryška)



Dear members of the European Society of Pathology, dear colleagues and friends,

It is my great honour and pleasure to address you for the first time as the

President of our Society.

I take the presidency with very humble feelings and with huge respect to previous presidents, who made our Society really great. The French philosopher Bernard de Chartres used to compare us to dwarfs perched on the shoulders of giants. He pointed out that we can see more and farther than our predecessors, not because we have keener vision or greater height, but because we are lifted up and borne aloft on their gigantic stature. Thus, I only hope that I will fulfil your expectations and move ESP a couple of steps further in the right direction.

Firstly, I want to express my sincere and deep thanks to all Officers and members of the Council, who served the Society during their periods. My thanks belong to our immediate past President, Prof. Holger Moch, his predecessor, Prof. Dina Tiniakos, and to our Secretary, Prof. Aurelio Ariza. I can hardly express how much I have learned from them during the last years. It is good to know that despite the fact that they are now leaving their posts, they will be still active in the ESP agenda,

and we can exploit their experience for the benefit of our Society.

If you participated in the ESP General Assembly you already know that another key ESP Expert who leaves his office is Prof. Peter Schirmacher, who served as Chair of the Education Subcommittee. It is not only because his 2-year period is over now, but most importantly because he was unanimously elected as our new President-Elect. The vacant post of Chair of the Education Subcommittee has been filled by another great candidate, Prof. Xavier Matias-Guiu from Spain. ESP also has a new Secretary, as Prof. Janina Kulka from Hungary was elected to this position. Last, but certainly not least - two members of the ESP Council are also leaving – Profs. Glen McCluggage and Anastasia Konstantinidou. The newly elected members of the Council are Profs. Jean-Christophe Sabourin (France) and Marta Cohen (United Kingdom). I wish them all a lot of energy in their new positions. I am absolutely sure that all together we will make a great and productive team.

So, how was ESP doing during the last two years and what should we expect from the future? I took over the office from Prof. Holger Moch after two extremely difficult years. Nobody would ever imagine that during Holger's presidency we would be forced to transform our major activities as last two congresses to virtual meetings, that we would cease all face-to-face meetings and switch to Zoom, MS Teams or Webex conferences (honestly - how many of you even HEARD these terms before the Covid-19 era?). Thus, the world pandemics made Prof. Holger's presidency extremely challenging. Yet, with his patience, wisdom and energy, he

successfully navigated ESP ship through the troubled waters of these two turbulent years and he leaves the Society stronger than ever before. We have learned a lot - not all issues have to be solved personally, and digital technologies can save a lot of time and traveling. Still, everybody is now looking forward to the release of strict regulations and to having our meetings in person again.

What are the challenges today and what will we face in the near future? Besides developing and strengthening our digital educational resources with new webinars, virtual preceptorships, and online courses, we will need to invest a lot of time and energy in upcoming changes in the European legislation, namely in the in-vitro diagnostics regulation (known as IVDR). This can completely change the life of every pathologist, at least of those working in the EU. The probably well-meant intention of EU representation to improve safety of our patients by strict quality control of individual diagnostic methods (instruments, tests, kits) may - and probably will - change into a nightmare of excessive bureaucratic obstacles, complications, and additional costs with very little (if any) real improvement of quality of our work. ESP representation (in particular our former Secretary, Prof. Aurelio Ariza) invested a lot of time and energy to mitigate the impact of this legislation on our daily life. We can only hope that the efforts of ESP, who acts not alone but together with our partners within the Biomedical Alliance (a unique initiative of 36 leading European medical societies), will be successful.

After the forced break, we will renew our activities - organisation of ESCoP

courses, ESP Academy, our young members start visiting European Advanced Training Centers with the financial support of ESP under the Giordano Fellowship programme. This means that we sincerely hope that the life of our Society will return to normal.

I am writing this text only couple of days after the end of our 33rd European Congress of Pathology (ECP), which had to be still almost exclusively virtual. I say: "almost exclusively", because this year we managed to bring at least a small group of pathologists to Gothenburg, where the congress was supposed to take place.



Virtual ECP 2021: Another three eventful pathology days have come to an end, filled with 96 live sessions. 2,718 participants from 94 countries went virtual with us

We could experience at least a glimpse of the atmosphere which we know so well from our past "traditional" congresses. This light at the end of the tunnel was a promise that if nothing really bad happens, our next congress in Basel should have the usual form again. Thanks to our presence in situ, we were able to organise a brand-new type of sessions, which we called "Highlights of the day". The panel of experts could discuss the most stimu-

lating, interesting, and challenging sessions of the day and - based on the feedback from the participants - this was a real success. We plan to keep this event for the future.



Highlight Sessions from Gothenburg: If you have not registered for the ECP but are intrigued about what you might have missed: You can still register now and get access to all ECP sessions until the end of November 2021!

The ECP 2021 was awarded 18 CME points by the European Accreditation Council for Continuing Medical Education – these are also available for on-demand content!

The Congress, despite its virtual format, was a success. We had 2718 registrations, represented by 94 countries, with UK, Germany and Spain leading the way. 1343 abstracts were submitted, and 146 bursaries awarded. There were 20 Industry Symposia and 17 Virtual Exhibitors.

I wish to express here my sincere thanks and acknowledgement to all members of the Scientific Committee, to the representation of the Swedish Society of Pathology, and to our congress organising company, CPO Hanser. They all did a great job and I believe you agree with me that this congress was great.



Preparations for next year's ECP in Basel are already well underway and we will keep you posted on the progress

I am looking very much to meeting you all in person next year at the 34th ECP in Basel, Switzerland (3-7 September 2022).

Yours sincerely,
Aleš Ryška

Message from the Editor

(By Prof. Marina Kos)



Dear colleagues and friends,

Another virtual congress is behind us. Hopefully it is the last one in this format and next time we will be able to meet in person.

The congress was very successful, no doubt because the first virtual one in Glasgow has given the organisers an important experience, and our expectations were a bit different than from a "live" congress. The welcome message by Prof. Holger Moch, President of the ESP and Prof. Göran Elmberger, Chair of the Organising Committee was cordial as always, accompanied by a short video about Gothenburg, making me regret even more that I couldn't be there in person.

In this issue of our Newsletter Prof. Ryška is giving his review of the Congress, as ESP President always does, and I am just going to share my own impressions with you.

This Congress was somewhat different than the previous ones (virtual or live), presenting some very interesting and useful sessions like several Joint Special Sessions (courses and symposia) of ECP and IAP, ESGO and ESTRO, ICCR & IACR, and also - for the first time - with Japanese Society (about molecular profiling). Courses dedicated to WHO blue-books with new classifications were also very useful and interesting. Swedish Society of Pathology also included the traditional Arkady Rywlin Slide Seminar that always presents interesting and rare cases which may be encountered in routine histopathology.

Keynote Lectures on Human cell atlas and Diversity of mutations in mesenchymal neoplasia, their detection and diversity given by Profs. Muzlifah Haniffa and Julia A. Bridge respectively, were very interesting, the topics and presenters were well chosen, and everyone could find something to their liking. The same can be said about the Industry Symposia, although they were mostly dedicated to pulmonary pathology. Special surprise was the new Juan Rosai Lecture, dedicated to the memory of the great man and pathologist, given this year by John K.C. Chan, who knew Prof. Rosai personally because he spent 6 months with him, and he also spent some time with Prof. Dorfmann. He briefly introduced us to Dr Rosai's achievements and gave an extremely interesting lecture on history and morphology of Rosai-Dorfmann disease.

We always expect a lot from Simeonides lecture, and rightly so, because this year it was given about NASH, its origin and future, by Prof. Tiniakos.

“Highlights of the day” at the end of each congress day were very useful, especially for those members who for some reason could not listen to some topics, and they were presented each day by a panel of experts who also gave a short review of the day and discussed the quality and importance of certain topics. This way, anyone who could not listen to some of them could return later, because it is possible to listen to the recorded lectures until the end of November. One of the examples that diagnostic problems which pathologists encounter every day should not be underestimated was confirmed by the presence of many listeners to the short course about appendiceal diseases. Also, the future of pathology and the importance of education of new forces in pathology was addressed in Joint Special Session ESP & Trainees & IT in Pathology about training pathologists for the digital era. Later in the Newsletter the Trainee Subcommittee inform us about the virtual event they organised with a very intriguing title “Lost in the lab”....

All in all, I think that this Congress was a huge success, even though it was virtual. Perhaps many people decided to attend because they didn't have to travel, and the registration fee was lower. That is surely very convenient, but still, in my opinion, nothing can replace meeting friends and colleagues face to face, and I hope with all my heart that we shall meet live in Basel next year. The presentation of Basel and the site of the Congress by Prof. Gieri Cathomas was very attractive,

and the programme is certainly going to be interesting as well.

At the General Assembly the election of new President-Elect, Secretary of the Society and two new members of the ESP Council were confirmed. You can find the report about it by the former Secretary of the Society, Prof. Aurelio Ariza. Apart from news about the Congress, in this Newsletter you will also find some new (and hopefully interesting) contributions, like interviews that might be interesting to members, the first of which is provided by our Associate Editor, Prof. Karoline Lackner and her colleague Dr Verena Stangl. We also start with presentations of National Societies, their activities and members. Breaking the ice is Prof. Andrzej Marszalek with the presentation of the Polish Society of Pathology. News from the European Cancer Organisation (ECO) and the usual contributions like the review of recently published books and list of future events is also included, so in the end I wish you all a pleasant reading!

Prof. Marina Kos

Introducing the new Secretary

(By Prof. Janina Kulka)



Dear Col-
leagues and
Friends,

I would like to thank all of you for approving my nomination for the ESP

Secretary position by your votes during the Gothenburg General Assembly on the 31st August 2021. Thank you most sincerely for your confidence.

I feel deeply honoured, meanwhile I'm very pleased for the opportunity to work together with a good friend, the new President, Prof. Aleš Ryška, as well as with the Executive Committee, the Council, the Advisory Board and the administrative leaders of the ESP for the benefit of our prosperous Society. I'm fully aware that following Prof. Aurelio Ariza and his predecessor, Prof. Ilmo Leivo in this position is not an easy task: the bar has been set very high, as we say in Hungary in similar situations. Nevertheless, I'll try my best and I'll dedicate my energy, my time and my creativity to fulfill the expectations that a Secretary of the European Society of Pathology may face.

As a member of the Executive Council, the Educational Committee and the Advisory Board I followed the work and admired the devotion of recent great leaders of the ESP: Prof. Fátima Carneiro, Prof. Han van Krieken, Prof. Pierre Bedossa, Prof. Dina Tiniakos, Prof. Holger Moch. As a member of the Breast Pathology Working Group of the ESP, I have been following the high-quality professional activities of the Society in this field. It was also my pleasure to contribute a small piece of the puzzle to the wonderful ESP history book by Andrew Wilson.

I feel especially proud because this is the first time in this Society's history that a woman fills the post of Secretary in the Executive Committee. I think it is also without precedent that both the President and the Secretary of ESP are from countries that are among the young members

of the European Union. Our dedication to Europe and to the European Society of Pathology will guide both of us in our duties and activities.

Prof. Janina Kulka

Message from the former Secretary

(By Prof. Aurelio Ariza)



Dear members of the ESP,

The procedure for the election of President-Elect, Secretary, and two members of the Council of the European Society of Pathology (ESP)

was completed at the virtual General Assembly held at the European Congress of Pathology (ECP) in Gothenburg.

At ECP Gothenburg 2021 two officers and two members of the Council demitted office upon completion of their terms. The two officers were the President-Elect (Prof. Aleš Ryška, Czechia) and the Secretary (Prof. Aurelio Ariza, Spain). In agreement with the ESP Statutes and Bylaws, the election of President-Elect and Secretary requires, in the first place, asking for the advice of the Nomination Subcommittee (which is composed of the active past presidents) and then presenting that opinion to the Council for discussion and vote. Following that procedure, the Council nominated Prof. Peter Schirmacher (Germany) for President-Elect

and Prof. Janina Kulka (Hungary) for Secretary. Those two nominations were announced in the ESP Newsletter, in which the membership at large was invited to present other proposals.

I, as ESP Secretary at the time, received no other proposals and, therefore, proceeded to request from the virtual General Assembly in Gothenburg the approval of the election of Prof. Schirmacher as President-Elect and, subsequently, of Prof. Kulka as Secretary. The General Assembly voted by a majority in favour in both cases. Thus, as of 31 August 2021, Prof. Peter Schirmacher and Prof. Janina Kulka became ESP President-Elect (2021-2023) and Secretary (2021-2025), respectively.

As for the election of members of the Council, the ESP Statutes and Bylaws specify that proposals have to be requested from the Nomination Subcommittee, the Council, and the membership at large. From these various sources I received several proposals. After deliberating these proposals at its March 2021 virtual meeting, the Council decided to nominate the following two persons for members of the Council: Prof. Marta Cohen (United Kingdom) and Prof. Jean-Christophe Sabourin (France). For each of these two nominations I requested the approval of the virtual General Assembly in Gothenburg, which voted in favour by a majority in each case.

In consonance with the aforesaid appointments, the virtual General Assembly also witnessed the conclusion of the mandates of Prof. Holger Moch (Switzerland) as President and Prof. Dina Tiniakos (Greece) as Past President, as well as the completion of the terms of Prof. Anastasia

Konstantinidou (Greece) and Prof. Glenn McCluggage (United Kingdom) as members of the Council. Their excellent work for the ESP was warmly recognised. Additionally, the General Assembly was informed of the appointment of Prof. Xavier Matias-Guiu (Spain) as new Chair of the Education Subcommittee, a post left vacant by the election of Prof. Shirmacher as President-Elect. Information related to the Trainee Subcommittee included the appointment of Dr Alexandra Vilaia (Romania) as Chair, Dr Seung Hyun Lee (United Kingdom) as Co-chair, and Dr Daniel Pinto (Portugal) as Adviser and liaison with the Education Subcommittee.

The virtual General Assembly at ECP Gothenburg 2021 also approved honorary memberships for Prof. Pierre Bedossa (France) and Prof. Marco Santucci (Italy), thus recognising their many years of service to the ESP.

With its governing bodies once more renewed as prescribed by its Statutes and Bylaws, the ESP started at ECP Gothenburg 2021 a new two-year period under the presidency of Prof. Aleš Ryška. That period, which will include the congresses of Basel (2022) and Dublin (2023), will hopefully be free of the annoying pandemic constraints so graciously endured by Prof. Holger Moch during his presidency. Thank you, Holger! Good luck, Aleš!

Finally, feeling deeply honored for the privilege of having served the ESP through all these fulfilling years, I would like to thank the steady support received from its members, leaders, and HQ personnel. As I hand the Secretary's torch over to Janina, I wish her the best in

chronicling the thrilling fights and feats of European pathology in the hectic time.

Kindest regards to you all,

Aurelio

ESP Interviews Series

TOPIC:


Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities

Goeppert B, Folseraas T, Roessler S et al.,
Hepatology 2020;72:1253-126

Interviewer:

Dr Verena Maria Stangl

*Diagnostic & Research Institute of Pathology,
Medical University of Graz*



Interviewee:

Prof. Benjamin Goeppert *Department of
General Pathology, University Hospital Hei-
delber*

Dr Verena Stangl, a fourth-year trainee at the institute of Pathology, Graz, Austria recently interviewed Prof. Benjamin Goepfert, a pathologist specialised in Hepato- and Hematopathology from the Department of Pathology at the University Hospital in Heidelberg on his publication "Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities". In this work he, Trine Folseraas, Stephanie Roessler, and colleagues lead by Prof. P. Schirmacher (Department of Pathology, Heidelberg, Germany) and Prof. T. Karlsen (Oslo University Hospital Rikshospitalet, Norway), showed that primary sclerosing cholangitis-associated biliary tract cancer (PSC-BTC) has an extrahepatic morpho-molecular phenotype, regardless of the anatomical site of the tumour and therapeutic targets.

Dr Stangl: Prof. Goepfert, you are currently working as a senior physician for general pathology and pathological anatomy at the Heidelberg University Hospital. When and why did you choose this subject? How long have you been working at Heidelberg University Hospital and what distinguishes this institute in your opinion?

Prof. Goepfert: Studying medicine, I was interested in diagnostic subjects with their variety and the possibility to understand diseases based on morphological changes. After my graduation from medical school in Tübingen, however, it was not easy to get a residency position in pathology. Therefore, I started my training at the Institute of Clinical Radiology at the University Hospital of Mannheim in 2006. In February of 2007, I changed to the Institute of Pathology at the University Hospital Heidelberg. What fascinates me about pathology is the exact classification of diseases by morphological and molecular criteria. In addition, it is possible to closely link patient

care and routine diagnostics with research. The Institute of Pathology in Heidelberg offers excellent conditions for this, including a wide range of cooperation opportunities, such as DKFZ and EMBL.

Dr Stangl: According to the institute's website, your specialties are hepatopathology and hematopathology. What fascinates you about these subjects?

Prof. Goepfert: This combination of specialties does not seem to be very common in Diagnostic Pathology, since I am occasionally asked about this combination. My main area of research has been hepatopancreatobiliary carcinogenesis since 2007. I have always been trying to take a morphomolecular view on my research topics, i.e., trying to correlate the morphologic and the molecular changes. Of course, the appropriate diagnostic expertise is essential for this approach. The occupation with hematopathology came much later, almost by chance - a leaving colleague had recommended me for this specialisation. This combination of specialties has enriched my daily diagnostic work enormously and the alternation of cases - in a nutshell: HPB pathology: much HE, little IHC vs. hematopathology: little HE, much IHC - has always saved me from monotony in routine diagnostics.

Dr Stangl: With your work "Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities", which was published in a clinical journal (Hepatology), you were able to show that PSC-BTC has an extrahepatic molecular-pathology phenotype, regardless of the anatomical site of the tumour.

How did you come up with this question? Are you particularly interested in the pathology of the biliary tract?

Prof. Goepfert: In 2007, starting as a resident at the Institute of Pathology, Heidelberg

University Hospital, "liver-related" research groups were focused on hepatocellular carcinoma (HCC). Cholangiocarcinoma (CCA) was obviously neglected at that time. Accordingly, there was no platform for CCA research, i.e., no tissue sample cohorts, no clinicopathological data, no CCA cell lines. This challenge and finding a neglected research topic motivated and inspired me for more than twelve years of working on hepatopancreatobiliary carcinogenesis now.

Dr Stangl: You have found some actionable targets here. What follow-up investigations are you planning?

Prof. Goepfert: Immediately after this Hepatology work, we focused on cholangiocarcinogenesis via intraductal papillary or tubulopapillary neoplasm of the bile duct (IPNB and ITPN, respectively) precursor lesions in a follow-up work (Goepfert et al., Gut, 2021). This type of precursor lesions is rather rare in non-PSC-BTC but are indeed quite frequent in PSC-BTC. Currently, we have several ongoing projects, which are dealing with PSC-BTC: These include methylome analyses and immuno-oncology. In addition, there is a direct spin-off project with our collaboration partners from Oslo, Norway (Tom Karlsen and Trine Folseraas) in which a subset of the collective is being analyzed by whole exome sequencing. Here, we hope to identify gene mutations not yet known in PSC-associated carcinogenesis.

Dr Stangl: What effect on therapy and clinical treatment do you expect that this insight will have?

Prof. Goepfert: PSC-BTC and non-PSC-BTC patients should be routinely tested in appropriate cancer centers for actionable targets we have identified in this and other publications (e.g., HER2, EGFR, BRAF, PD-L1). The precise anatomical and histomorphological subtyping of BTC is essential for the selection

of the appropriate test algorithm (e.g., small-duct iCCA). In addition, this work provides the basis for further research aiming to identify new potential therapeutic targets for BTC patients.

Dr Stangl: The demands of diagnosis in pathology have changed over the years, especially with the advancement of molecular pathology. In your opinion, where will this development lead us and what will its practical uses look like?

Prof. Goepfert: "The future of pathology is morphomolecular" (quotation from the German professional association of pathologists) – personally, I completely agree with this statement. However, it is rightly not called "moleculomorphological" in this quotation, and not only because of the better way of speaking! This means, morphology comes first and is the basis for any further action, and then, as a very important supplement, the molecular pathology joins in. Through the morphomolecular research in BTC, we have already realised that we need to pay even more attention to certain specific characteristics of the neoplasms. This is the case, for example, with small/large duct iCCA, IDH1/2 and FGFR testing or HER2 in gallbladder carcinomas. In the near future, more and more morphological features will become predictively relevant. The pathologist will thus recommend the appropriate testing strategy, ideally predict outcome and recommend therapeutic options by sitting at the microscope and running molecular tests. In a more distant future, when genome-, methylome-, and proteome-wide tests and their analyses become much faster and cheaper, we may not need to pay as much attention to morphological details anymore. However, in this "transitional phase", the duration of which we can only estimate, the constantly growing integrative morphomolecular knowledge will be very relevant for our patients.

Dr Stangl: What recommendations do you have for those entering pathology as regards their training and their scientific work?


Prof. Goepfert: Recognise that you stand on the shoulders of giants. However, do not be intimidated by this huge amount of

knowledge. Instead, try to acquire this expertise and use it as a solid basis to break new ground

When setting out on this study together with Trine Folseraas and Stefanie Roessler we summarized our aims as shown in this cartoon from our lab journal:



Stephanie Roessler



Trine Folseraas



Presenting the Polish Society of Pathology


(By Prof. Andrzej Marszalek)



In recent years the Polish Society of Pathology has focused on the implementation of standards and reimbursement for pathology services. In December 2017 a new Regulation on the

“Organization of Healthcare in the field of Pathology” was published by the Minister of Health. In accordance with this act, a series of steps were undertaken. In 2020 more than 100 authors took part in writing a collection of “Organizational and Operational Standards for Pathology” along with “Guidelines for Pathology Departments”. The primary version was checked in ten pathology departments for pilot use. Subsequently, pathology experts, governmental officials from the Ministry of Health, the National Health Fund, and the Agency for Medical Technology and Tariffs, in addition to public consultations, returned more than 1700 comments. The final version of the document (almost 700 pages) was approved by the Ministry of Health in September 2020 and sent to all pathology departments. Based on this document a further two steps were taken.



The aforementioned document was used as base to prepare accreditation standards for pathology departments and is supposed to be signed by the Minister of Health in the coming days.



This document was supplemented by an implementation handbook, which should make the process of preparation for accreditation simpler for pathology departments. In April 2021 a pilot programme for reimbursement of pathology services was started in 24 departments selected by the Ministry of Health. By the end of this year there are expected to be sufficient results to allow for the definition of prices for particular groups of pathology procedures. We have an optimistic view of the future. The standards are ready, and the accreditation and financial issues are in hand.

Message from the ESP Trainee Subcommittee

(By Dr Alexandra Vilaia and Dr Lee Seung Hyun)




We hope this letter finds you well. The ESP Trainee Subcommittee has kept itself very busy during the past six months. We would like to use this opportunity to share the news and to describe the projects we have been working on since April.

We have had two major events since our appointment in March: recruiting new trainees to our team and organising trainee sessions at the 33rd European Congress of Pathology.

In April a call for new team members of the ESP Trainee Subcommittee was sent out. We successfully recruited trainees from a diverse background to the Trainee Subcommittee and supporting team. We sent out an application call for new team members for the ESP Trainee Subcommittee. We received a large number of applications from trainees across various regions of Europe. The trainees were enthusiastic, full of creative ideas and passionate about pathology. We would like to

thank again for their interest and congratulate every one of them.



Top from left to right: Antonia Syrnioti, Frances Reznitsky, Anton Baysa

Bottom from left to right: Jelena Dzambas, Pui-Yuen Lee

It is our pleasure to introduce to you our new team members: Dr Anton Baysa (Norway), Dr Frances Reznitsky (Denmark), Dr Pui-Yuen Lee (The Netherlands), Dr Jelena Dzambas (Serbia) and Dr Antonia Syrnioti (Greece). Further, we believe solid teamwork and brainstorming are crucial to develop execute creative projects. We would like to extend our welcome to the following trainees to our supporting team: Ntala Chara (UK), Simona Costache (Romania), Juan Fernandez-Perez (Spain), Irmira Michalek (Poland), Carlos Faria (Portugal) and Lavisha Punjabi (Singapore). We are happy to see that the Subcommittee is gaining visibility and more residents expressed their interest to get involved in our activities. We would like to invite all trainees to engage with us, to participate in our projects and to join our meetings. Your ideas and suggestions are always welcome, and we

thank you for attending and participating at the events organised by the ESP.

We would like to congratulate all trainees who participated at the congress and all those who presented their work during the amazing three days of the 33rd European Congress of Pathology. The Trainee Subcommittee had some quite busy days during the event: on the first day we had the privilege of starting with an interesting and cutting-edge session “Training pathologists for the digital era – e-pathology, e-education and e-learning” organised jointly with the Education Subcommittee and IT/Computational Working Group. During this session we presented the results of the survey conducted between June and July 2021. The survey was designed to gather European trainees’ views on their access and usage of digital pathology and their experience and expectations regarding e-learning. This survey revealed some interesting results, and we very much encourage you to watch the recording if you missed the session. You can also find presentations on topics delivered by exceptional speakers, including e-medicine and the patient, the challenges of digital transformation, quality control in digital pathology, as well as AI and pathologists.

Two trainee events followed our first session’s success: The General Assembly of the Trainee Subcommittee and the first virtual social event. For this year we adapted to the new format for the General Assembly. We invited trainees to share their experience during the pandemic, and to let us know how the ESP and the ESP Trainee Subcommittee can help. The trainee speakers and participants contributed their diverse perspectives during this hour of interesting round-table

discussion. We would like to take this opportunity to thank our moderators: Dr Gitta Turowski (Norway), Prof. Karoline Lackner (Austria), Dr Daniel Pinto (Portugal) and the trainee speakers, who made this round-table discussion possible: Dr Irene Carretero (Spain), Dr Anton Baysa (Norway), Dr Christos Topalidis (Greece) and Dr Marin Zacharias (Austria).

Following the General Assembly of the Trainees, many trainees joined the virtual social event. We thought the current circumstances shouldn’t stop us from having fun together, so we invited trainees to join us for a virtual escape room. The event was fully booked, and we would like to thank all those who joined us. The overall feedback from participants was positive. Despite it being a virtual event, we had a chance to meet new people and work together to solve the mystery. Congratulations again to team Desmosomes who won the first place. It was also the coolest team name!

During our second day at the 33rd ECP, we joined the Digestive Disease Working Group for a special Joint Session on Pancreatic and biliary inflammatory pathologies. Four top notch speakers prepared four interesting educational cases. They also shared their approaches and pearls of wisdom on this challenging topic of pancreatobiliary pathology. The session was well received by both trainees and senior pathologists. A large number of attendees was interested in the topic, and the speakers were asked many questions.

We would like to thank everyone who attended the sessions, and we kindly remind you that you can access all the recordings on the congress' platform until 30th November 2021.

We believe ECP2021 was a great success for the Trainee Subcommittee. We will strive to deliver more new ideas and interesting sessions next year. We have already started working on the sessions for the next congress, so please keep an eye on your email and our social media accounts!


We would like to finish by thanking every one of you for your support for the past months and for your participation at the 33rd European Congress of Pathology. We hope that we will have the chance to meet with you in person soon, but until then, stay safe and keep an eye on our future activities! If you have any ideas or questions for us do not hesitate to contact us at esp.traineesubcommittee@esp-pathology.org.

On behalf of ESP Trainee Subcommittee,
Alexandra Vilaia
Seung Hyun Lee

NEWS FROM THE EUROPEAN CANCER ORGANISATION (ECO)

(By Paul Gasc, Special Projects Lead, European Cancer Organisation)

Time To Act: European Cancer Organisation calls for urgent action as one million Cancer cases are undiagnosed in Europe due to Covid-19



Nearly one million Cancer cases in Europe are being missed due to Covid-19, according to data intelligence published by the European Cancer Organisation.

The findings, a stark reminder of the challenges facing cancer care services in Europe during the pandemic, coincided with the launch of Time To Act, European Cancer Organisation's campaign to urge the public, cancer patients, policymakers and healthcare professionals to ensure Covid-19 does not continue to undermine the fight against Cancer.

The data intelligence places the scale of the crisis in sharp focus:

- An estimated one million Cancer cases could be undiagnosed in Europe
- An estimated 100 million Cancer screening tests were not performed in Europe during the pandemic, leading to later stage diagnoses and decreased overall survival
- Up to 1 in 2 people with potential cancer symptoms were not urgently referred for diagnosis

- 1 in every 5 cancer patients in Europe is currently still not receiving the surgical or chemotherapy treatment they need


The data intelligence and the Time To Act campaign tools, available in over 30 languages, were presented in a virtual launch event in May 2021 and national virtual events taking place between June and November 2021, with contributions from European political leaders including EU Health Commissioner Stella Kyriakides, MEPs from the European Parliament's Special Committee on Beating Cancer (BECA), the Director General of DG SANTE, Sandra Gallina, as well as several national Health Ministers.

Dr Matti Aapro, E.C.O. President, said: "The findings bring the impact of Covid-19 on Cancer into sharp focus. We desperately need urgent measures at the highest level of European policy to address the cancer backlog, restore confidence in cancer services and tackle workforce/supply shortages."

Learn more about the campaign and get involved: www.TimeToActCancer.com

Obituary of Professor Michael Newton Marsh

(By Prof. Arzu Ensari)



Dear Colleagues,

With much sadness I bring to your attention that Professor Michael Newton Marsh passed away on the 13th of July 2021 from metastatic prostate cancer. He suffered from disseminated disease and chemotherapy side effect with exhaustion and nausea.

Marsh was a physician who had great respect and interest for pathology. His research on Coeliac disease based on histopathology and morphometry and his highly intelligent professional achievements on intestinal immunopathology certainly gained the respect of scientists and practicing pathologists on a global scale. He is also well known for his masterpiece published in 1992 in Gastroenterology, Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('coeliac sprue'). This unique single author manuscript has gained over 2000 citation and is considered the most solid foundation and landmark of coeliac disease histology forming the basis of Marsh Classification. Over the last few months Marsh had been working on his own Obituary in collaboration with myself and Professor Kamran Rostami. It is an amazing life story. Even after his passing, he has ensured that his legacy lives on with same tenacity, precision, extraordinary articulation and passion he displayed while he was alive!

He will be remembered for his unique and historical role in coeliac disease mucosal pathology characterisation and interpretation.

I had the privilege of being his PhD student and the honour of being a long-term colleague and a close friend. I am deeply sad about his passing.

He will be greatly missed...

Arzu Ensari, MD, PhD

Professor in Pathology
Ankara University Medical School

Recently Published Books

(By Prof. Karoline Lackner)

Title: Diagnostic Pathology: Forensic Autopsy E-Book

Authors: Mary Ann Sens and Rhome Hughes

Publisher: Elsevier Health Sciences 2021
ISBN: 0323756182, 9780323756181

Forensic Autopsy E-Book is a part of the Diagnostic Pathology textbook series. This comprehensive textbook authored by two prominent experts provides guidance on key topics in forensic pathology with particular emphasis on patterns of toxicology including new drugs, infant and child death as well as trauma. The book also provides information on the performance of routine and complicated autopsies and is augmented by an organized content featuring key factors for each chapter and a large number of high-quality images. toxicology including new drugs, infant and child death as well as trauma. The book also provides information on the performance of routine and complicated autopsies and is augmented by an organized content featuring key factors for each chapter and a large number of high-quality images.

Title: Diagnostic Pathology Hepatobiliary and Pancreas

Authors: Laura Webb Lamps MD, Maria Westerhoff MD, Sanjay Kakar

Publisher: Elsevier

ISBN-10 : 0323776205

ISBN-13 : 978-0323776202

This recently released 3rd Edition of **Hepatobiliary and Pancreas of the Diagnostic Pathology** series covers all areas of neoplastic and nonneoplastic diseases of the pancreas and liver. It is an excellent resource summarizing most recent clinical, pathological, and molecular knowledge in the field. The book provides algorithmic guidelines for complete pathology reports complemented by high quality illustrations, information on immunohistochemical markers and other ancillary techniques as well as recent advances in molecular pathology. Details from the 2019 WHO Classification of Tumors of the Digestive System reflecting recent changes and updates are other useful features. An eBook version is available facilitating searches for text, figures and references.

Title: Diagnostic Pathology Bone

Authors: G Petur Nielsen, Andrew E Rosenberg

Publisher: Elsevier

ISBN-10 : 0323765335

ISBN-13 : 978-0323765336

This 3rd Edition of **Bone** of the Diagnostic Pathology series is a valuable resource covering all areas of bone pathology. It is an easy-to-use up-to-date reference providing diagnostic guidelines on non-neoplastic as well as neoplastic entities in bone pathology, updates from the 5th Edition of the WHO Classification of Tumors of Soft Tissue and Bone and overviews on radiologic imaging features in a richly full-

coloured illustrated textbook. It is an ideal as a day-to-day reference as well as a reliable training resource which is also available as eBook version.

Title: Gattuso's Differential Diagnosis in Surgical Pathology

Authors: Vijaya B. Reddy, Odile David M, Daniel J. Spitz, Meryl H. Haber

Publisher: Elsevier

ISBN-10 : 0323661653

ISBN-13 : 978-0323661652

The 4th edition of the popular **Gattuso's Differential Diagnosis in Surgical Pathology** is a useful and reliable reference providing concise description of neoplastic and non-neoplastic diseases complemented by diagnostic algorithms facilitating the differential diagnostic work-up of complex and challenging cases. The new edition features several updates including personalized/precision medicine especially in particular with respect to the immunotherapies in many cancers, the new classification of neuroendocrine tumors, the new classification and updates of follicular variant of papillary thyroid carcinoma, and a new section on the most common metastatic tumors and utilization of ancillary techniques for diagnosis and molecular studies.

According to © Doody's Review Service, 2021, Jaclyn M Plotzke, MD (University of Michigan Medical School) Score: 98-5 Stars! "This is an excellent resource and can be used as a quick reference guide for diagnostic features, differential diagnoses, helpful ancillary studies, clinical features, and diagnostic helpful hints.

Upcoming Webinars and Conferences

(By Prof. Karoline Lackner)

Conferences

Breast Pathology for All Ages: Diagnostic Pearls and Pitfalls (And How to Stay Out of Trouble)

13-15 January 2022

USCAP Interactive Center, Palm Springs, CA, USA

ICSH 2022: 16. International Conference on Skin Histopathology

7-8 February 2022

Amsterdam, Netherlands

USCAP Annual Meeting

19-24 March 2022

Los Angeles Convention Center and JW Marriott

Los Angeles, CA, USA

19th International Conference on Breast Pathology and Cancer Diagnosis

24-25 March 2022

Madrid, Spain

European Lung Cancer Conference

30 March - 2 April 2022

Prague, Czech Republic

ICLC 2022: 16. International Conference on Lung Cancer

23-24 June 2022

Vienna, Austria

International Conference on Gastroenterology and Liver
18-19 July 2022
Amsterdam, Netherlands

Challenges in Hematopathology
12-14 April 2022
USCAP Interactive Center, Palm Springs, CA, USA

Immersive Cytopathology Experience (ICE): Focus on Interventional Diagnostics
22-26 May 2022
San Sebastián, Spain

Digital Pathology & AI Congress
14-15 June 2022
New York, USA

ICDP 2022: 16th International Conference on Digital Pathology
18-19 November 2022
Paris, France

ESP Webinars and Seminars

Digestive Diseases: Precursors of epithelial malignancy in the digestive system: what's new? Part2 (upper GI and Liver), 13 October 2021

Biomarkers testing, 20 October 2021

Nephropathology: Chronic ABMR, 27 October 2021

PD-L1 testing: 3 November 2021

Pulmonary Pathology: Update on lung cancer predictive biomarker testing, 17 November 2021

Nephropathology: Complement-mediated disease, 1 December 2021

Digital Pathology Seminar
Jointly organised with ESO
11-12 December 2021

Thymic-Mediastinal Pathology: Thymic hyperplasias - classification and differential diagnosis, 15 December 2021

Nephropathology: Immunohistochemical typing of amyloid on fixed paraffin-embedded samples by an automatic procedure, 23 February 2022

Other Webinars

12th Annual ENETS Postgraduate Course, 19 February 2022



Digital Pathology & Image Analysis Training School (DP&IATS), 24-25 February 2022

Bone and soft tissue tumours – Madrid course, 8-11 June 2022



European Society of Pathology – Webinars Portal

Click to access the recordings of ESP webinars!



 Excellence in pathology for optimal patient care

COMING SOON

Cholangiocarcinoma
Virtual Education Series



LEARN MORE ►

© 2021, Incyte Biosciences International Sàrl. All rights reserved
Date of prep: July 2021 DE/PEMA/NP/21/0031.

Z4-36250; Date of preparation: August 2021



AVAILABLE NOW!



In collaboration with AstraZeneca and MSD, the Prostate and Ovarian Cancer Virtual Education Series are available now.

The Prostate and Ovarian Cancer Virtual Education Series are now available through the European Society of Pathology education portal.

Modules on diagnostic testing in prostate and ovarian cancer have been co-created with expert pathologists and molecular geneticists in collaboration with AstraZeneca and MSD.

Modules:

- **Theory:** Learn more about the background to prostate and ovarian cancer including epidemiology, homologous recombination repair pathway defects and tumour biology, diagnostic workflows and treatment options
- **Practical:** Understand the concepts and techniques involved in tissue and gBRCA testing in prostate and ovarian cancer. Explore the use of ctDNA testing in prostate cancer, as well as genomic instability testing in ovarian cancer
- **Best Practice:** Learn the latest best practice guidance on molecular sequencing in prostate and ovarian cancer from testing to reporting

Each module includes a short summary video and a self-assessment exercise to support your learning.

An evaluation form will be shared with ESP members soon to assess the impact of the modules on training and understand the request for any additional educational programs.

These educational materials are co-developed and funded by AstraZeneca and MSD.
This educational curriculum is not supported by CME points.
This educational series is for pathologists only.

